The Bombay High Court has issued a stern warning against the continued commercial use of a company’s name and trademarks after judicial winding up, emphasizing that such acts not only flout court orders but also endanger public health through the unregulated sale of prescription drugs. This ruling underscores the judiciary’s duty to enforce compliance with corporate insolvency outcomes and protect consumers from fraudulent corporate remnants.
Background & Facts
The Dispute
Following the winding up of Elder Pharmaceutical Ltd. by order dated 4 December 2017, pharmaceutical products bearing the company’s name and trademark continued to circulate in the market. These included prescription antibiotics and other controlled medications, raising serious concerns about their authenticity, safety, and legal status. The applicants alleged that former directors and the Chief Operating Officer, Mr. Anuj Saxena, were orchestrating this unauthorized activity, exploiting the company’s residual brand recognition to profit illegally.
Procedural History
- The company was formally wound up on 4 December 2017 under the Companies Act, 2013.
- The Official Liquidator reported ongoing sales of products under the company’s name in Report No. 36 of 2022.
- The applicants filed Interim Application (L) No. 26515 of 2021 seeking urgent relief.
- Mr. Anuj Saxena, though identified as the key actor, was not originally named as a respondent.
Relief Sought
The applicants sought immediate directions to halt the sale of counterfeit pharmaceuticals, implead Mr. Anuj Saxena as a respondent, and appoint an independent expert to assist the court in assessing the scale and impact of the violation.
The Legal Issue
The central question was whether the continued sale of pharmaceutical products under the name of a company that has been judicially wound up constitutes a violation of court orders and public interest, and whether individuals responsible for such acts can be held accountable even if not originally named as parties.
Arguments Presented
For the Petitioner
Ms. Jane Cox argued that post-winding up commercial activity under the company’s name is a direct defiance of the court’s winding up order, which extinguishes the company’s legal personality. She cited State of Maharashtra v. M/s. R. K. Industries to assert that any post-winding up transaction is void ab initio. She further emphasized that the sale of prescription drugs without regulatory oversight poses a grave threat to public health under Section 26 of the Drugs and Cosmetics Act, 1940.
For the Respondent
The counsel for the Ex-COO acknowledged the existence of unsold stock but claimed it was being liquidated in good faith under the Official Liquidator’s supervision. He contended that no criminal intent was proven and that the company’s trademark was not actively misused but merely remained on existing inventory. He opposed impleadment, arguing that Mr. Saxena’s involvement was not substantiated by documentary evidence.
The Court's Analysis
The Court rejected the notion that post-winding up sales could be justified as mere liquidation of inventory. It held that once a company is wound up, its legal capacity to engage in commercial activity ceases entirely. The continued use of its name and trademark for sale of pharmaceuticals is not a passive act but an active deception of consumers and regulators.
"The sale of prescription drugs under the name of a defunct company is not a commercial lapse - it is a public health emergency masquerading as a corporate oversight."
The Court noted that the Official Liquidator’s report confirmed the presence of such products in the market, and that the absence of Mr. Saxena as a party was a procedural gap, not a substantive defense. The Court emphasized that natural justice requires accountability to follow the actors, not just the corporate shell. The appointment of an amicus curiae was deemed necessary to independently verify the extent of the violation and advise on regulatory coordination with the Drug Controller.
The Court also clarified that the filing of a reply affidavit by an unjoined party does not confer legal standing; however, once impleadment is permitted, such filings become admissible. The Court exercised its inherent powers under Section 151 of the Code of Civil Procedure to ensure compliance with its orders and protect public welfare.
The Verdict
The applicants succeeded. The Court held that post-winding up sale of pharmaceuticals under a defunct company’s name violates court orders and endangers public health. Mr. Anuj Saxena was impleaded as a respondent, and an amicus curiae was appointed to assist the court. The respondents were directed to disclose his current residential address and cease all sales immediately.
What This Means For Similar Cases
Corporate Identity Cannot Be Exploited Post-Winding Up
- Practitioners must immediately report any post-winding up commercial activity under a dissolved company’s name to the Official Liquidator and the court.
- Any sale of goods bearing the name of a wound-up entity is void and may attract contempt proceedings.
- Regulatory authorities (e.g., CDSCO) must be notified to trace and seize such products.
Amicus Curiae Can Be Appointed to Enforce Compliance
- Courts may appoint independent experts to investigate breaches of winding up orders, especially where public safety is at stake.
- This expands the scope of judicial oversight beyond formal parties to include systemic risks.
- Legal teams in insolvency matters must now anticipate and prepare for third-party investigative interventions.
Impleadment of Key Individuals Is Permissible Even After Proceedings Commence
- Courts will permit amendment to implead individuals responsible for violations, even if they were not originally named, provided notice has been given and a reply filed.
- This prevents defendants from evading liability through procedural technicalities.
- Practitioners should routinely investigate and seek to implead officers, directors, or employees who continue to operate under the defunct entity’s name.
